Evaxion biotech to host conference call on evx-01 and evx-02 phase 1/2a data on july 8

Copenhagen, denmark, july 07, 2021 (globe newswire) -- evaxion biotech a/s (nasdaq: evax), a clinical-stage biotechnology company specializing in the development of ai-driven immunotherapies to improve the lives of patients with cancer, bacterial diseases and viral infections, announced today that it will hold a conference call to discuss phase 1/2a data on evx-01 and evx-02 on thursday, july 8, 2021.
EVAX Ratings Summary
EVAX Quant Ranking